RCS - Kanabo Group PLC - Kanabo appointed to BSI Steering Group Committee

KanaboAnnouncement

24/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221024:nRSX7908Da&default-theme=true

RNS Number : 7908D  Kanabo Group PLC  24 October 2022

RNS Reach

Kanabo Group Plc

("Kanabo" or the "Company")

 

Kanabo appointed to BSI Steering Group Committee

 

A New British Standard: Kanabo Group Kanabo Group has been invited to
co-develop standard specifications for the safety, quality and performance of
CBD vape products to ensure consistency of quality and consumer protection.

 

Kanabo Group plc (LSE:KNB) the pan-European medical cannabis company that
focuses on developing and commercialising cannabis-derived products for
medical patients and wellness consumers, has been selected as a steering group
member for the development of a British Standard for CBD non-tobacco Vape
products.

CBD Vape products provide an alternative method to consuming CBD, which has
been dominated by food and cosmetic products. Standardisation of the category
is currently minimal and has historically focused on the safety of electronic
components of CBD Vape products. The British Standards Institution ("BSI") has
announced a Publicly Available Specifications ("PAS") expected to be published
in early 2023 for CBD Vape Products to develop a standard specification for
their safety, quality, and performance, which will ensure consumer protection
while driving category growth.

PAS is a sponsored standardisation document compiled and co-developed by
industry experts and stakeholders, defining best practice with the goal of
introducing standardisation. The PAS is authored by a steering group
representing an equitable spread of stakeholder expertise and opinion. Kanabo
Group's appointment to the steering committee of PAS 13956 will leverage the
pioneering experience, research and development of the CBD and cannabis
specialist - including extensive clinical and validation activities, as well
as safety and efficiency tests conducted by the Group.

Headquartered in the UK with research and development facilities centred in
Israel (an established leader in the cannabis industry) the Pan-European
Kanabo Group is focused on developing and commercialising cannabis-derived
products for medical patients and wellness CBD consumers. This includes the
unique development of high-quality cannabis extract formulas and innovating
medical-grade vaporisers and non-combustible inhalation consumption solutions
with pharmaceutical grade production standards to produce the highest quality
high potency and vegan friendly CBD vape products for consumers. Kanabo
Group's experience and expertise will inform the BSI document to provide a
standard specification for the safety, quality, and performance of CBD Vape
products in order to ensure consumer protection under reasonable and
foreseeable conditions based on Kanabo's own self-regulated standards that
include comprehensive safety data, pharmaceutical grade manufacturing
practices and stringent product purity testing to ensure no dilutants are
used.

 

Avihu Tamir, CEO Kanabo Group Plc, said: "We are delighted to be included
within this PAS steering group. We have always taken a safety-first approach
to our CDB products and delivery devices, which includes educating consumers
about our products and their quality. We always undertake stringent safety and
efficacy studies as part of our product development programmes and are unique
in the industry in making these results available to the public. These
important developments will provide consumers with confidence and ultimately
shape the CBD Vape industry.

"Kanabo Group has plans to reach out to the UK Government's Medicines and
Healthcare products Regulatory Agency to highlight the PAS publication and
share their standards for testing the safety and efficacy of new products in
the hope that the same exacting process and consumer transparency will inform
the assessment and establishment of national standards."

 

For further information, please visit http://www.kanabogroup.com/ or contact
the following:

 Kanabo Group Plc             Via Vox Markets
 Investor Enquiries           kanabogroup@voxmarkets.co.uk

 Kat Perez / Richard Fabris
 Media Enquiries              nic.barnes@rkmcom.com

 Nic Barnes

 

About Kanabo Group Plc

Kanabo Group Plc is a leading developer and distributer of cannabis-derived
products and inhalation technologies for medical patients and non-THC products
for CBD consumers. Kanabo Group Plc was the first medicinal cannabis company
to IPO on London Stock Exchange and is made up of supply-chain specialist
subsidiaries, from cultivation consultancy to R&D to formula development
and distribution, including:

·    Kanabo Agritec Ltd, a cultivation consultancy supporting cannabis
businesses in developing new farms through infrastructural, research, and
product guidance. These farms deliver high-quality raw materials for Kanabo's
formulas and product line.

·    Kanabo Research Ltd, a wholly owned subsidiary of Kanabo Group Plc,
responsible for R&D, regulation, and quality assurance procedures.

·    The GP Service - a Kanabo Group Plc owned, NHS approved online
telehealth provider offering video consultations, online prescriptions,
treatment forms and access to both Kanabo medical-cannabis and wellbeing CBD
products.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFVDISLVFIF